ReWalk completes acquisition of rival AlterG
ReWalk has completed the acquisition of AlterG, which provides anti-gravity systems for use in physical and neurological rehabilitation.
Source: globes.co.il
Medtech Insight News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Medtech Insight. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Medtech Insight Today - Breaking & Trending Today
Nutromics Receives $14M for Development of Lab-on-a-Patch DNA Sensor Platform That Transmits Biometric Data in Real Time from Interstitial Fluid
Nutromics raises $14M to develop lab-on-a-patch DNA microneedle sensor that monitors biomarkers in interstitial fluid.
Source: darkdaily.com
Spotlight on IVDR - Cheers Slovakia! Seventh Notified Body designated under IVDR
After a nine month wait, a seventh Notified Body has at last been designated under the EU’s new In Vitro Diagnostic Medical Device Regulation (IVDR)…
Source: lexology.com
COVID-19 Medical Products Supply Chain Week in Review - May 2021 #2 | Alston & Bird
To embed, copy and paste the code into your website or blog: In the past week, the FDA revealed the future plan for its inspectional activities. In addition, President Biden announced a new July 4 vaccination target. Please see details for these and other supply chain developments below: On April 27, Medtech Insight posted an FDA document to a medical device firm, explaining the Office of Medical Device and Radiological Health Operations’ Remote Regulatory Assessment (RRA) program to determine medical device facilities’ compliance status. Under the RRA program, the FDA requests and discus...
Source: jdsupra.com
Decentralized Clinical Trials: Surviving & Thriving in the Clinical Research World of COVID-19
Decentralized Clinical Trials: Surviving & Thriving in the Clinical Research World of COVID-19 by Zach Henderson, Chief Commercial Officer, Glooko Zach Henderson, Chief Commercial Officer, Glooko As with so many aspects of our daily lives, the impact of the COVID-19 pandemic on clinical trials was both widespread and monumental. Thousands of trials—an estimated 80% of non-COVID-19 trials—came to a halt or were interrupted by the pandemic, which challenged the ability to conduct trials safely and effectively and was complicated by the reality that trials often deal with the populations mos...
Source: hitconsultant.net